Drug Industry Antitrust Act: Hearings Before the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, United States Senate, Eighty-seventh Congress, First [-second] Session, Pursuant to S. Res. 52 on S. 1552, a Bill to Amend and Supplement the Antitrust Laws, with Respect to the Manufacture and Distribution of Drugs, and for Other Purposes, 5-6. daļas

Pirmais vāks
U.S. Government Printing Office, 1961 - 4217 lappuses

No grāmatas satura

Saturs

Bieži izmantoti vārdi un frāzes

Populāri fragmenti

2944. lappuse - Secretary finds (1) that clinical or other experience, tests, or other scientific data show that such drug is unsafe for use under the conditions of use upon the basis of which the application was approved...
2858. lappuse - Labeling on or within the package from which the drug is to be dispensed bears adequate information for its use, including indications, effects, dosages, routes, methods, and frequency and duration of administration, and any relevant hazards, contraindications, side effects, and precautions...
2972. lappuse - The members of the Combined Contact Committee of the American Drug Manufacturers Association and the American Pharmaceutical Manufacturers' Association made outstanding contributions in the development of standards for ampuls and tablets.
2848. lappuse - ... (n) In the case of any prescription drug distributed or offered for sale in any State, unless the manufacturer, packer, or distributor thereof includes in all advertisements and other descriptive printed matter issued or caused to be issued by the manufacturer, packer, or distributor...
2609. lappuse - As a charter of freedom, the act has a generality and adaptability comparable to that found to be desirable in constitutional provisions.
3144. lappuse - CHLOROMYCETIN is a potent therapeutic agent and, because certain blood dyscrasias have been associated with its administration, it should not be used indiscriminately or for minor infections. Furthermore, as with certain other drugs, adequate blood studies should be made when the patient requires prolonged or intermittent therapy.
2953. lappuse - DC, then and there to testify what you may know relative to the subject matters under consideration by said committee.
2723. lappuse - He who orders does not buy; and he who buys does not order.
2953. lappuse - ... authorized and directed, upon request from the Commissioner of Patents, to furnish full and complete information with respect to such questions relating to drugs as the Commissioner may submit concerning any patent application. The Secretary is further authorized, upon receipt of any such request, to conduct or cause to be conducted, such research as may be required.
2854. lappuse - I am taking the liberty of sending a copy of this letter to the other members of your committee.

Bibliogrāfiskā informācija